Cannabinoid Derivative Isolation via Chromatographic Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for using cannabis for medical purposes, such as smoking, face challenges including the presence of carcinogens and toxins, difficulty in maintaining proper dosing, and low bioavailability of cannabinoids, while also struggling to isolate individual cannabinoids at high purity levels for therapeutic use.
Innovation Solution
Development of novel ligands for cannabinoid receptors, represented by compounds of a specific formula, which can act as therapeutics to modulate the activity of CB1, CB2, and other receptors, potentially treating a wide range of diseases with improved safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If smoking cannabis is used for medical purposes, then cannabinoids are delivered to patients, but carcinogens and toxins are introduced into the body
Solution Approach 1:
The patent extracts and isolates individual cannabinoids from the complex cannabis plant matrix through chromatographic separation methods. This extraction process removes the desired cannabinoid compounds while leaving behind the harmful carcinogens and toxins in the plant material, allowing delivery of pure therapeutic agents without the associated harmful factors.
Solution Approach 2:
The patent employs chromatographic media and separation techniques as intermediary systems between the cannabis plant and the patient. These intermediaries selectively bind and separate cannabinoids from other plant constituents, enabling the delivery of therapeutic compounds while filtering out harmful substances through the intermediary separation process.
2Ease of manufacture
If smoking cannabis is used for medical purposes, then cannabinoids are delivered to patients, but dosing control becomes difficult
Solution Approach 1:
The patent segments the complex cannabinoid mixture into individual, isolated compounds through chromatographic separation. Each cannabinoid can be precisely quantified and dosed as a separate entity, enabling accurate measurement and control of therapeutic doses without the variability inherent in whole-plant extracts or smoked material.
Solution Approach 2:
The patent changes the physical and chemical parameters of cannabinoid delivery from inhalation of combusted plant material to administration of purified compounds in controlled formulations. This parameter change enables precise dosing through standardized concentrations and delivery mechanisms, eliminating the dosing variability associated with smoking.
3Ease of manufacture
If smoking cannabis is used for medical purposes, then cannabinoids are delivered to patients, but bioavailability of target compounds is low
Solution Approach 1:
The patent extracts pure cannabinoids from the plant matrix, removing barriers to absorption present in whole-plant material. The isolated compounds can be formulated in delivery systems optimized for specific routes of administration, significantly improving bioavailability compared to smoking where combustion and plant matter interfere with compound delivery.
Solution Approach 2:
The patent changes the delivery parameters from combustion-based inhalation to controlled administration of purified compounds. This may include formulation in carriers, use of different administration routes, and optimization of compound stability, all of which improve the reliability and bioavailability of target compounds compared to smoking.
4Quantity of substance
If extraction processes are used to isolate cannabinoids, then individual cannabinoids can be obtained, but high purity levels are difficult to achieve
Solution Approach 1:
The patent applies segmented chromatographic separation where the complex cannabinoid mixture is divided into multiple fractions through sequential elution. Each fraction contains increasingly purified individual cannabinoids, with purity levels enhanced through multiple separation stages and selective elution conditions that resolve closely related compounds.
Solution Approach 2:
The patent employs dynamic chromatographic conditions where flow rates, solvent compositions, and temperature are adjusted during the separation process to optimize resolution. These dynamic parameter changes enable high purity isolation of individual cannabinoids that have similar chemical properties and would be difficult to separate under static conditions.
Data Source
AI summary
This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.